Inthera Bioscience AG, a Wädenswil, Switzerland-based pre-clinical stage oncology company targeting the inhibition of protein-protein interactions with innovative small molecule chemistry, secured the second €4.7m tranche of its Series A financing, bringing the total amount to €9.6m.
Backers included M Ventures, Aglaia BioMedical Ventures, and Novo Seeds.
The company also announced that three senior Pharma and Biotech Industry members joined its management team. They are:
– Bernd Hentsch, who joins the company as Chief Development Officer,
– Ralph Lindemann who joins the company as Chief Scientific Officer, and
– Monique Schiersing who joins the company as Chief Operating Officer.
Bernd Hentsch, Ph.D. has held various senior positions in the European Biotech industry. Prior to joining Inthera Bioscience he was Chief Development Officer at 4SC AG, a German clinical stage oncology company and TopoTarget A/S, a Danish clinical stage oncology company. Prior to TopoTarget A/S, Bernd has held other R&D related positions, e.g. in Germany at Merck KGaA, Darmstadt, the German Cancer Research Center, Heidelberg, and at the Walter and Eliza Hall Institute in Melbourne, Australia.
Ralph Lindemann, Ph.D. joins Inthera Bioscience from Merck KGaA, Darmstadt, Translational Innovation Platform Oncology. He has 15 years of experience in translational research and drug discovery and an academic track record in chromatin-based therapeutics.
Monique Schiersing, M.Sc., MBA served previously as Investment Director at the Roche Venture Fund, F. Hoffmann–La Roche AG’s corporate venture fund. In this role Monique served as Director on the board of various Biotech companies in the US as well as in Europe, amongst others Macrolide Pharmaceuticals, Inc., Minoryx Therapeutics S.L., or mySugr GmbH. Prior to this role, Monique held positions as Principal at BankInvest in Copenhagen and Global Alliance Director at Roche Pharma Partnering in Basel.
Led by CEO Uli Kessler, Inthera Bioscience is a private biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. Rationally designed, these orally bioavailable molecules display hot spot residues on a non-peptidic backbone merging the versatility of small molecules with the specificity of biologics. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently entering the preclinical development stage.